Nazanene H Esfandiari1, David T Hughes, Huiying Yin, Mousumi Banerjee, Megan R Haymart. 1. Department of Medicine, Division of Metabolism, Endocrinology, and Diabetes (N.H.E.); Department of Surgery, Division of Endocrine Surgery (D.T.H.); Department of Surgery (H.Y.); Department of Biostatistics (M.B.); and Department of Medicine, Division of Metabolism, Endocrinology, and Diabetes and Division of Hematology/Oncology (M.R.H.), University of Michigan, Ann Arbor, Michigan 48106.
Abstract
CONTEXT: Total thyroidectomy with central lymph node dissection is recommended in patients with medullary thyroid cancer (MTC). However, the relationship between disease severity and extent of resection on overall survival remains unknown. OBJECTIVE: The aim of the study was to identify the effect of surgery on overall survival in MTC patients. METHODS: Using data from 2968 patients with MTC diagnosed between 1998 and 2005 from the National Cancer Database, we determined the relationship between the number of cervical lymph node metastases, tumor size, distant metastases, and extent of surgery on overall survival in patients with MTC. RESULTS: Older patient age (5.69 [95% CI, 3.34-9.72]), larger tumor size (2.89 [95% CI, 2.14-3.90]), presence of distant metastases (5.68 [95% CI, 4.61-6.99]), and number of positive regional lymph nodes (for ≥16 lymph nodes, 3.40 [95% CI, 2.41-4.79]) were independently associated with decreased survival. Overall survival rate for patients with cervical lymph nodes resected and negative, cervical lymph nodes not resected, and 1-5, 6-10, 11-16, and ≥16 cervical lymph node metastases was 90, 76, 74, 61, 69, and 55%, respectively. There was no difference in survival based on surgical intervention in patients with tumor size ≤ 2 cm without distant metastases. In patients with tumor size > 2.0 cm and no distant metastases, all surgical treatments resulted in a significant improvement in survival compared to no surgery (P < .001). In patients with distant metastases, only total thyroidectomy with regional lymph node resection resulted in a significant improvement in survival (P < .001). CONCLUSIONS: The number of lymph node metastases should be incorporated into MTC staging. The extent of surgery in patients with MTC should be tailored to tumor size and distant metastases.
CONTEXT: Total thyroidectomy with central lymph node dissection is recommended in patients with medullary thyroid cancer (MTC). However, the relationship between disease severity and extent of resection on overall survival remains unknown. OBJECTIVE: The aim of the study was to identify the effect of surgery on overall survival in MTC patients. METHODS: Using data from 2968 patients with MTC diagnosed between 1998 and 2005 from the National Cancer Database, we determined the relationship between the number of cervical lymph node metastases, tumor size, distant metastases, and extent of surgery on overall survival in patients with MTC. RESULTS: Older patient age (5.69 [95% CI, 3.34-9.72]), larger tumor size (2.89 [95% CI, 2.14-3.90]), presence of distant metastases (5.68 [95% CI, 4.61-6.99]), and number of positive regional lymph nodes (for ≥16 lymph nodes, 3.40 [95% CI, 2.41-4.79]) were independently associated with decreased survival. Overall survival rate for patients with cervical lymph nodes resected and negative, cervical lymph nodes not resected, and 1-5, 6-10, 11-16, and ≥16 cervical lymph node metastases was 90, 76, 74, 61, 69, and 55%, respectively. There was no difference in survival based on surgical intervention in patients with tumor size ≤ 2 cm without distant metastases. In patients with tumor size > 2.0 cm and no distant metastases, all surgical treatments resulted in a significant improvement in survival compared to no surgery (P < .001). In patients with distant metastases, only total thyroidectomy with regional lymph node resection resulted in a significant improvement in survival (P < .001). CONCLUSIONS: The number of lymph node metastases should be incorporated into MTC staging. The extent of surgery in patients with MTC should be tailored to tumor size and distant metastases.
Authors: E Modigliani; R Cohen; J M Campos; B Conte-Devolx; B Maes; A Boneu; M Schlumberger; J C Bigorgne; P Dumontier; L Leclerc; B Corcuff; I Guilhem Journal: Clin Endocrinol (Oxf) Date: 1998-03 Impact factor: 3.478
Authors: Reese W Randle; Courtney J Balentine; Glen E Leverson; Jeffrey A Havlena; Rebecca S Sippel; David F Schneider; Susan C Pitt Journal: Surgery Date: 2016-11-11 Impact factor: 3.982
Authors: P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill Journal: Ir J Med Sci Date: 2016-04-15 Impact factor: 1.568
Authors: Rachel K Voss; Lei Feng; Jeffrey E Lee; Nancy D Perrier; Paul H Graham; Samuel M Hyde; Frances Nieves-Munoz; Maria E Cabanillas; Steven G Waguespack; Gilbert J Cote; Robert F Gagel; Elizabeth G Grubbs Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch Journal: Ann Surg Oncol Date: 2019-09-23 Impact factor: 5.344
Authors: Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote Journal: Thyroid Date: 2016-10-18 Impact factor: 6.568
Authors: Garth F Essig; Kyle Porter; David Schneider; Debora Arpaia; Susan C Lindsey; Giulia Busonero; Daniel Fineberg; Barbara Fruci; Kristien Boelaert; Johannes W Smit; Johannes Arnoldus Anthonius Meijer; Leonidas H Duntas; Neil Sharma; Giuseppe Costante; Sebastiano Filetti; Rebecca S Sippel; Bernadette Biondi; Duncan J Topliss; Furio Pacini; Rui M B Maciel; Patrick C Walz; Richard T Kloos Journal: Thyroid Date: 2016-10-11 Impact factor: 6.568